期刊
PURINERGIC SIGNALLING
卷 18, 期 1, 页码 61-81出版社
SPRINGER
DOI: 10.1007/s11302-021-09821-7
关键词
Cancer; Purinergic system; Phenolic compound; Melanoma; Rosmarinic acid; Chemotherapy
资金
- Universidade Federal da Fronteira Sul -UFFS
This review article explores the potential of retinoic acid (RA) as an adjuvant in melanoma treatment through modulating the purinergic cellular pathway. The study proposes several hypotheses for using RA to mitigate the Warburg effect, block P2X7, and act as an antagonic molecule of the P2Y12 receptor in cancer treatment. While further research is needed, this work serves as a foundation for future studies on the promising compound.
Cancer cases have increased significantly in Brazil and worldwide, with cutaneous melanoma (CM) being responsible for nearly 57,000 deaths in the world. Thus, this review article aims at exploring and proposed hypotheses with respect to the possibility that RA can be a promising and alternative compound to be used as an adjuvant in melanoma treatment, acting on purinergic signaling. The scarcity of articles evidencing the action of this compound in this signaling pathway requires further studies. Considering diverse evidence found in the literature, we hypothesize that RA can be an effective candidate for the treatment of CM acting as a modulating molecule of purinergic cellular pathway through P2X7 blocking, mitigating the Warburg effect, and as antagonic molecule of the P2Y12 receptor, reducing the formation of adhesive molecules that prevent adherence in tumor cells. In this way, our proposals for CM treatment based on targeting purinergic signaling permeate the integral practice, going from intracell to extracell. Undoubtedly, much is still to be discovered and elucidated about this promising compound, this paper being an interesting work baseline to support more research studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据